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Transfusion of blood cell components is frequent in the therapeutic arsenal; it is globally 
safe or even very safe. At present, residual clinical manifestations are principally inflam-
matory in nature. If some rare clinical hazards manifest as acute inflammation symptoms 
of various origin, most of them linked with conflicting and undesirable biological material 
accompanying the therapeutic component (infectious pathogen, pathogenic antibody, 
unwanted antigen, or allergen), the general feature is subtler and less visible, and 
essentially consists of alloimmunization or febrile non-hemolytic transfusion reaction. 
The present essay aims to present updates in hematology and immunology that help 
understand how, when, and why subclinical inflammation underlies alloimmunization and 
circumstances characteristic of red blood cells and – even more frequently – platelets 
that contribute inflammatory mediators. Modern transfusion medicine makes sustained 
efforts to limit such inflammatory hazards; efforts can be successful only if one has a 
clear view of each element’s role.
Keywords: inflammation, transfusion, allergy, blood components, leukocytes, platelets, erythrocytes, 
alloimmunization
iNTRODUCTiON
Historically, inflammation was viewed as the compendium of all four stigmas: “rubor, calor, dolor, 
and tumor”; this concept fits well with the theory of humors; bloodletting – and surrogates (e.g., 
leeches and suction cups) – have long been applied to treat, if not cure, inflammation symptoms. 
As a matter of fact, iron depletion caused by bloodletting happened to alter bacterial growth and 
ameliorate certain disease conditions, as already observed by Tissot in 1761 (1). The Hippocratic 
theory of humors was probably the first to introduce the relationship between blood and inflam-
mation, though using wrong descriptors. In its earliest days, transfusion was clearly associated with 
acute inflammation, though the connection was not acknowledged as such: indeed, the very first 
reported serious adverse events (SAEs) of “modern” transfusion in the early twentieth century were 
dual in nature: first, immune-hematological [i.e., antigen–antibody (ABO)] conflicts, and second, 
blood-borne and blood-transmitted infections, such as syphilis and malaria (2). Both conditions – 
presenting as very severe – were later on acknowledged as being dominated by cytokine storms and 
standing for acute inflammatory reactions (often lethal) (3, 4).
The concept of inflammation has been largely revisited by modern internal medicine; series of 
autoimmune and auto-inflammatory diseases have thus been acknowledged. No organ-specific 
disorder is actually beyond the scope of the large clinical inflammation spectrum, since a number of 
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neurological disorders (5) – as well as many cardiovascular lesions 
especially the atheroma plaque deposit (6) – are inflammation 
stigmas. The causality of inflammation in organ-specific lesions 
is being questioned, but combinations of genetic predisposition, 
lifelong hygienic habits, other environmental factors, and infec-
tious triggers are commonly evoked. For decades now, clinical 
inflammation has not been restricted to acute Hippocratic symp-
toms and is acknowledged to present as more subtle symptoms 
of varying degrees.
We believe two major achievements have helped reconsider 
clinical inflammation as it may apply to transfusion medicine 
and cell, tissue, and organ transplantation. Neither was intended 
to apply to this discipline; however, the first is the (re)discovery 
of the danger signal theory, as proposed by P. Matzinger at the 
NIAID, NIH, in the 1990s, after its seminal conceptualization 
by E. Metchnikoff at the Pasteur Institute 100 years earlier. This 
discovery is basic to immunology and helps reframe the reading 
of immunology (7). The second is the conceptualization of the 
microbiota’s role in immunity – initially presented as governing 
what Ph Sansonetti (at the Pasteur Institute in Paris) called “war 
and peace” at the mucosal surfaces. This concept helped show 
that inflammation spans the whole spectrum, from physiology 
to pathology (8–10). It has since been suggested that healing 
(e.g., of tissue attrition or organ lesions) is the ultimate step of 
inflammation (11, 12).
TRANSFUSiON AND iNFLAMMATiON: 
FROM BeDSiDe TO BeNCH
From the bedside, one can consider two periods in relation to 
transfusion-related hazards, especially inflammation. The initial 
period concerns acute symptoms of SAEs: inflammation is 
observed among other symptoms such as shock. Those accidents 
were principally reported with reference to their major cause(s): 
the ABO conflict, transfusion-transmitted bacterial, viral, or 
parasitic infections, and allergy. In 1983, a novel cause of trans-
fusion-transmitted SAE was described: transfusion-related acute 
lung injury (TRALI) (13–15). Interestingly, this SAE is ascribed 
to a dual cause: an Ag/Ab conflict – within the human leukocyte 
antigen (HLA) or, more rarely but more severely, the human 
neutrophil antigen (HNA) systems – and an inflammatory layer: 
sepsis, stress, etc. Besides conflicting Abs (when identified, i.e., 
in two out of every three cases on average), the principal actors 
are leukocytes recruited or residing in lung capillaries. The 
TRALI concept prompted a reinvestigation of SAEs in transfu-
sion and acknowledgment of serious inflammatory cases. This is 
also true for allergy: though one cannot exclude the possibility of 
pathogenic IgE transfer, it is rather felt that such an occurrence 
cannot account for one-third of adverse events (AEs) varying in 
severity (16, 17). Transfusion allergy is, in general, considered to 
present like allergy, though it is not believed to have a link with 
atopy or involve allergens or Abs specific to allergens. It is rec-
ognized as one of the most frequent inflammatory consequences 
of transfusion (18).
In summary, despite this is over-simplistic, one may acknowl-
edge that inflammation symptoms manifested by a transfused 
patient and in relation with the transfusion process has two 
principal causes: it is either due to the transfer of pathogenic 
material collected from the donor or it is due to a conflict between 
high affinity receptors found on the recipients’ cells or plasma 
molecules and ligands brought by the transfused component.
The majority of AEs in patients receiving blood (recipients) 
manifest either allergy or febrile non-hemolytic transfusion reac-
tions (FNHTRs), both being clearly inflammatory conditions 
(19). Leukocytes transferred with blood were ascribed to as the 
principal causes of TT inflammation. Systematic “leucoreduc-
tion” – often inappropriately, but nevertheless officially, termed 
“leucodepletion” – was proposed at the start of the millenium 
by many countries or blood transfusion systems. However, 
leucoreduction has neither been become recommended nor 
a mandatory practice for mitigating inflammatory responses 
but is instead used to limit transfusion-transmitted viral risks 
as many “serious transfusion-associated viruses” are intracel-
lular. Leucoreduction was principally aimed to reduce the risk 
of transmitting the Creutzfeldt–Jakob prion (20). Veterans 
of transfusion medicine very well recall the time when every 
single transfused patient was “shaking and heating,” manifest-
ing common symptoms that were subsequent to the therapy 
and introduced as such to patients (when patients happened 
to receive information). Pre-storage leucoreduction was then 
acknowledged to have largely improved comfort and safety in 
patients, suggesting a deleterious role for leukocytes (21, 22). 
When leucoreduction is performed post-storage (e.g., at the 
bedside, prior to the infusion of the blood component), inflam-
matory manifestation is intermediate, largely suggesting that not 
only leukocytes but also their secreted content play a role in the 
transfusion inflammation pathophysiology (23).
However, as the transfused patient profile changed, more 
and more recipients benefited from platelet components (PCs). 
This major change took place more or less at the same time as 
the implementation of systematic hemovigilance, and it soon 
became obvious that PCs – though representing no more than 
10% of issued blood components – provide between one-quarter 
to one-half of reported AEs (24). This means that leukocytes 
were not the only cells associated with transfusion-associated 
inflammation.
Another population of patients benefiting from frequent trans-
fusion episodes, sickle-cell disease patients, led to an important 
discovery: first, they manifest complex hemolytic reactions that 
involve activated complement and present as essentially inflam-
matory (25) and second, they are subjected to the most frequent 
rate of alloimmunization among tracked cohorts of transfused 
patients (26). This prompted specialists to also examine the 
inflammatory potential of stored erythrocytes.
THe MAJOR iDeNTiFieD CAUSeS 
OF TRANSFUSiON-ASSOCiATeD 
iNFLAMMATiON
There is good evidence in favor of an undesirable role for residual 
leukocytes in transfused patients; blood banks can get rid of such 
residual leukocytes with a high degree of efficacy by using filtra-
tion methods. Leucoreduction is highly recommended by the 
European Community and the American Association of Blood 
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Banks with a target of no more than 106 residual leukocytes 
per blood component after filtration (27, 28); most pre-storage 
methods allow scores of leucoreduction ranging between 2 
and 5 × 105 residual leukocytes per component (29). However, 
clinical observations suggest that other constituents of pre-stored 
and leucoreduced cellular blood components still lead to some 
inflammatory manifestations in patients.
To simplify and summarize, pro-inflammatory factors in labile 
blood components fall into one of the following four categories: 
(1) infectious pathogens transmitted by blood that cause bacterial 
sepsis, acute or chronic viral infection, or acute parasitic infection 
(and often hemolysis); (2) pathogenic, undesirable, Abs (caus-
ing hemolysis when encountering target Ags, especially when 
capable of binding complement; causing TRALI, depending 
on circumstances or predisposition; causing Reagin-mediated 
allergy; and causing a number of non-hemolytic situations, 
now ascribed to FNHTRs); (3) leukocytes and their content, 
and especially their high loads of pro-inflammatory cytokines, 
chemokines, and the like, collectively termed biological response 
modifiers (BRMs); and (4) (pro)inflammatory material linked to 
platelet and erythrocyte pathophysiology, especially when cellular 
blood components [PCs and packed red blood cell components 
(pRBCCs)] are stored over time and undergo so-called storage 
lesions, which consist of extracellular vesicle emission and the 
freeing of membrane-bound molecules and intracellular content, 
either iron (erythrocytes) or BRMs (platelets). It is not unusual 
that extracellular vesicles are called microparticles.
The first two categories are chiefly inflammatory, involving two 
principal mechanisms: first, the triggering of a cytokine storm, 
with broad consequences for all systems, exposing the patient 
to multivisceral failure and severe central neurologic disorders. 
Second, if erythrocytes are ultimate targets of the Ab or infectious 
pathogens, there is acute hemolysis with obvious consequences. 
This essay will not further discuss such cases. Neither will it dis-
cuss the specific case of bacterial contamination of PCs, largely 
related to the storage temperature of 22 ± 2°C; 18.5 severe cases 
per million PCs delivered are recorded annually according to the 
latest French hemovigilance records; and one such case happens 
to be lethal, on average (30).
The latter two categories reveal that inflammation is not only 
the result of substantial levels of BRMs secreted by leukocytes, 
platelets, or lysed erythrocytes but also of products secreted as a 
consequence of cell–cell encounters after the blood component 
has been transfused. Cell–cell interactions occur mainly between 
(i) donor transfused cells and recipient circulating cells and (ii) 
donor transfused cells and recipient vascular endothelium cells. 
Transfusion is a dynamic process, but it is often regarded as 
the passive infusion of therapeutic components (31). This view 
is misleading and a source of errors for the interpretation of 
transfusion-associated inflammation.
MODeLS OF TRANSFUSiON-ASSOCiATeD 
iNFLAMMATiON HiT
This section will address three main issues: (1) how transfusion 
can act as a stress for the recipient, subsequently triggering an 
immune defense; (2) how blood components can present with 
varying degrees of stress signals, accompanied by pathogenic 
storage lesions; and (3) how the stage is set for a recipient’s 
adaptive immune response to donor cell Ags. These three 
points parallel three major aspects of the transfusion process 
or chain: donor-linked characteristics, additional pathogenic 
steps during blood component production, and recipient-linked 
characteristics.
Transfusion as a Stress and Donor-Linked 
Characteristics Account for Recipients’ 
inflammatory Symptoms
Transfusion is an unnatural process in the sense that the exchange 
of body parts between individuals – other than mothers and their 
embryos or fetuses – is not part of the human evolutionary pro-
gram. Each individual’s blood has potentially unique biological 
characteristics. Thus, when foreign cellular material, is tentatively 
grafted into a recipient, the latter identifies it as foreign and poten-
tially dangerous, even when it has a therapeutic purpose. Indeed, 
many studies have shown that platelets express a large variety 
of pathogen sensors, promptly engaged by several kinds of the 
so-called pathogen-associated molecular pattern (molecules) or 
PAMPs (if stresses are infectious in nature) or damage-associated 
molecular pattern (molecules) or DAMPs (if stresses are internal, 
such as Abs). This has been principally found relative to platelets 
(32, 33), and similar findings have been reported for erythrocytes 
(34). Furthermore, donor platelets express HLA class I Ags that 
differ in general from those of recipients. Donor cells are thus 
likely to be sensed as foreign by recipients’ circulating and vessel-
lining leukocytes, which are prone to signaling this through 
a pro-inflammatory response, or by vessel endothelial cells. 
Experimental data suggest that endothelial cells can also signal 
the detection of foreign material by mounting a pro-inflammatory 
response (35–38). In general, though it is still difficult to link with 
certainty a host’s innate inflammatory response with unmanipu-
lated donor cells, the danger theory of innate immunity would 
largely predict it in transfusion.
Recent data offer newer evidence supporting the hypothesis. 
First, a large Canadian clinical trial recently reported that age and 
sex of donors influenced the outcome of transfusion in recipients, 
more than any other factor (e.g., age of blood or pathology) (39, 
40). Although there is now good evidence that there are differ-
ences between males and females in pathology and in particular 
in immune responses to infection or vaccines and inflammation 
processes, the gender issue has not been specifically addressed 
satisfactorily in transfusion medicine (41): this is perhaps a path 
for further investigation.
Our own investigations have shown that donors present great 
variation in the genes coding for CD40L; CD40L was investigated 
because platelets are the major purveyors of sCD40L in the body 
(42), and this BRM influences both innate and adaptive immunity 
(43). CD40L gene polymorphism was found to influence the pres-
entation of secreted CD40L (44). It has been hypothesized that 
this genetic characteristic of donors may affect pro-inflammatory 
secretion of donated platelets in BCs (45, 46). This type of result 
is plausible as well for other BRMs.
TABLe 1 | Blood product storage and biological response modifier release.
Packed red blood cell concentrates Platelet concentrates Plasma for direct therapeutic use
Usual storage 
time
42 days 5 days 1 year
Main  
product 
transformation
Leucoreduction
Irradiation
Pediatric preparation
Deplasmatization/washing
Volume reduction
Cryopreservation
Reconstituted blood
Automated cell separation
Centrifugation
Leucoreduction
Platelet additive solutions
Occasionally pathogen
Reduction or inactivation technology
Irradiation
Deplasmatisation/washing
Cryopreservation
Volume reduction
Leucoreduction
Freezing/thawing
Solvent-detergent
Chemical and light pathogen inactivation
Lyophilization
Lesion  
storage
Shape changes from a normal biconcave  
disk to echinocytes and spheroechinocytes
↑ Ammonium
↑ Free Hb in plasma
↑ K+ from
↓ ATP
↓ 2,3 DPG to <10% of original levels 
– replenished
↓ Labile proteins, e.g., complement, fibronectin, 
and coagulation factors ↓ to negligible
↓ Na+
↓ pH
↓ NADH
↑ Bioactive substances (free Hb, hemin, 
microvesicles, iron, cytokines, lipids, and 
enzymes)
↓ S-nitrosohemoglobin (SNO-Hb) bioactivity
Shape changes from discoid to spheroid
↑ Activation (↑ release of granular contents)
↑ Proteolysis
Altered platelet surface receptor expression
↑ Platelet aggregates
Decreased mean platelet volume (MPV)
↑ Volume and density heterogeneity
↑ Procoagulant activity
↑ Platelet apoptosis
↓ pH, pO2, and glucose
↑ pCO2
↑ Lactate production
↑ Glucose consumption
↓ Calcium ion flux
ATP/ADP ratio change
↓ Mitochondrial oxidative respiration
↓ Fibrinogen binding
↑ Proteases
↑ Oxidation of Pro, Arg, Lys, Thr, Glu, or Asp 
side chains
↑ Cleavage of protein backbone
↑ Incorporation of lipid peroxidation products 
into Cys, His, or Lys residues
↑ Formation of advanced glycation end products
↑ Lipid peroxidation
Released/
increased  
factor
MPs, IL-8, TNF-α, RANTES, NAP-2, Gro-α, 
MIP-1α, SDF-1, ENA-78, TGF-β, …
Microvesicles
EGF, ENA-78, Gro-α, IL-1β, IL-6, IL-7, IL-8, 
IL-27, Lyso-PCs, sOX40L, PAI-1, PDGF-AA, 
PF4, RANTES, sCD40L, TGF-β, TNF-α, 
VEGF, β-TG, …
Microvesicles
Mitochondrial DNA
MPO, ECP, and histamine increase after thawing
IL-1β, IL-4, and IL-10 increase with freeze/thaw 
cycles
MMP-7 increases with the number of freeze/
thaw cycles
IL-4, IL-12, and TNF-α increase with the number 
of freeze/thaw cycles …
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Blood Component Manufacturing and 
Storage Lesions with Pro-inflammatory 
Consequences in Recipients
A large body of reviews has documented this topic. We may 
consider two sets of data for illustrative purposes: one explores 
the secretory capacity of stored platelets over time or of platelets 
undergoing stress lesions upon collection, processing, and storage 
(47–50); the other explores the age of blood – and more precisely, 
the age of pRBCCs – at delivery. Both data sets incorporate 
diverse readouts: BRMs, oxidants, free iron, and extracellular 
vesicles (51–54). Despite such extracellular vesicles are reported 
to carry pro-inflammatory factors (55), some anti-inflammatory 
properties of extracellular vesicles have been reported (56), sug-
gesting a fine-tune balance of inflammatory responses in relation 
of extracellular vesicles, likely depending on their sizes (57), 
origin, and abundance.
To summarize, it is generally reported that longer PC stor-
age is accompanied by greater production of pro-inflammatory 
cytokines, which make up the majority of anti-inflammatory 
products (58–62) (Table 1). If leukocytes are still present in the 
PCs, leukocyte- and platelet-originating cytokines and other 
BRMs potentiate each other over time (63). Our own group has 
reported that there is a direct relationship between (i) the secre-
tion of sCD40L [proved to exert a pathogenic effect in certain 
recipients, together with companion BRMs Ox40L and IL-27 (64, 
65)] and the component shelf life; and (ii) between the net amount 
of sCD40L (alongside potentiating molecules IL-13 or MIP-1α) 
and the manifestation of an inflammatory AE in the recipient 
(62). Similar findings exist for mitochondrial DNA (66–68). 
In addition, it has also been proposed that the techniques used 
to obtain PCs influence pro-inflammatory reactions, as these 
techniques do not expose platelets to the same stress (62, 69). 
Together, these observations strongly suggest the platelet storage 
lesions have a role in PC induced inflammation and its balance 
in transfused patients.
The situation for erythrocytes is even more complex. Substantial 
experimental evidence suggests that the age of erythrocytes, and 
the subsequent freeing of iron, is directly responsible for inflam-
mation in experimental models, both in vivo and ex vivo/in vitro 
(70–74). Thus far, however, clinical trials have consistently failed 
to support this hypothesis (75). It should nevertheless be noted 
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that this is extremely difficult to investigate and that further trials 
are necessary to resolve the matter (76).
Consequences of inflammation in 
Recipients: Manifestations of 
Adaptive immunity
There are two main consequences of inflammation in blood 
component recipients. One – alloimmunization to foreign Ags 
– is rather clear. The other is transfusion-related immune modu-
lation or TRIM. TRIM is a complex occurrence that involves a 
number of adaptive immune tools, of which suppressive CD8+ 
T cells, regulatory T (and probably B) cells, anti-idiotypic T cell 
clones, along with soluble HLA molecules and other supposed 
mediators (77–79). It must be made clear that, if the main visible 
consequence of immunization to foreign Ags is alloimmuniza-
tion, there is a likely strong T cell immunity; however, it seems 
difficult to catch it up, and the majority of published works focus 
on Ab production. One may hypothesize that T cell immunity 
and TRIM rather explain cases where immunization is not pro-
ductive in terms of Ab formation. Another consequence of TRIM 
is perhaps the likely depression of immune surveillance with the 
report of suspected increase of posttransfusion infections (that 
are quite well documented) and perhaps malignancies or organ 
dysfunctions (that are to be ascertained) (80–83).
Alloimmunization remains the most frequently reported AE 
of transfusion. It is often reported in pathologies where extended 
matching of red cells is difficult to achieve, for people needing 
repeated transfusions, such as sickle-cell disease or β-thalassemic 
patients. Indeed, as there are near 350 Ags on erythrocytes, a 
perfect match is unlikely. Recipient characteristics such as how 
well one presents HLA are also considered to have a major impact 
(84). In addition, residual leukocytes are highly potent immuniz-
ers (far more commonly in HLA groups than in HNA groups); 
platelets are also good immunizers in both HLA class I and HPA 
groups (85). However, it has been demonstrated that residual leu-
kocytes can influence the global immunization score: as shown 
in experimental models, stringent but incomplete leucoreduc-
tion minimizes alloimmunization, while strict leucoreduction 
reinforces it, supposedly by erasing the TRIM effect (84).
Yet in spite of several attempts to decipher innate immune 
mechanisms acting as layers of inflammation that fuel Ag 
presentation, the details of alloimmunization largely remain a 
mystery (86).
Last, another consequence of inflammation is the reported 
enhanced erythrocyte phagocytosis by spleen cells. Inflammation 
created by excess iron and nitric oxide (NO) freeing – perhaps 
linked with aged erythrocytes – would aggravate anemia instead 
of correcting it by bringing Hb/O2 (87). While there is good 
experimental evidence in favor of this pathophysiology, clinical 
relevance is not yet ascertained.
FROM BeNCH TO BeDSiDe: PATHS TO 
iMPROve PATieNTS’ SAFeTY
Pathophysiological studies of platelets reveal that any exposure to 
stress may have consequences. Depending on the nature of this 
stress, platelets can mobilize predefined patterns of BRMs (88, 
89). Indeed, contrary to what we might expect, given that they 
are anucleate, platelets do not indiscriminately release granule 
content through an all-or-nothing mechanism but rather exhibit 
stress-dictated processes (32, 90–93). This may explain why 
certain patients having received PCs manifest allergic reactions 
(where δ-granule BRMs predominate) or FNHTR/inflamma-
tion (where α-granule BRMs predominate) (Figure 1; Table 2). 
A readout in the PC leftover is given by the predominance of 
either IL-13 or MIP-1α in addition to sCD40L (62). Platelets 
are extremely reactive cells, and it is almost impossible to not 
pre-activate them while processing PCs for transfusion purposes. 
However, it has been made clear that the collection process, i.e., 
apheresis vs. recovered platelets from whole blood; platelets 
recovered from platelet-rich plasma vs. from buffy coats; PAS vs. 
plasma; pathogen reduction/inactivation vs. no additional safety 
measure; and in the case of apheresis, type of cell separator – and 
the length of storage are important parameters to control activa-
tion (59, 62, 65, 94–97). Despite conflicting data (98), it cannot 
be ruled out that ABO compatibility vs. identity also affects the 
outcome of platelet transfusion (99, 100), but probably not by 
triggering pre-activation. Furthermore, PCs are almost always 
HLA incompatible, at least for the majority of expressed class I 
Ags. This has not appeared to be deleterious in terms of clinical 
outcome – in the PLADO trial (98), for example, but consistent 
recommendations suggest that refractoriness to platelet transfu-
sion is better addressed with HLA-compatible PCs (97). The 
HPA case is barely addressed, unless a specific and pathogenic 
Ab is identified, or in the case of fetal/neonatal maternal incom-
patibility (101). Serious allergies, allergic reactions, or severe 
FNHTRs can be addressed – when further PC transfusions are 
needed – by washing the components. This process is neverthe-
less tedious as it may itself pre-activate the cells. Alternatively, 
some teams may absorb pathogenic BRMs on columns when 
available (102, 103). At present, there are parameters that cannot 
be controlled (recipients’ genetic characteristics and – to a large 
extent – donors’ characteristics) and those that can be partly 
controlled, i.e., manufacturing, ABO matching, and aging of 
the PCs (Table 3). Most efforts appear to focus on the last three 
issues to limit inflammation in recipients. Further investigations 
are needed to evaluate the actual impact of safety measures in PC 
recipients and determine whether efforts can be made to propose 
matching procedures that can calculate the most important fac-
tors to limit inflammatory responses in patients.
For pRBCCs, the appropriate strategy may be very simple or 
very complex. In theory, it should be simple if one considers that 
the enemy is alloimmunization, which concerns inflammation. 
To limit the risk of immunization, an improvement of blood group 
Ag matching would be ideal; however, considering the volume of 
blood components to be issued to millions of recipients, this is 
simply not achievable on a routine basis. Efforts are being made 
to facilitate matching for at-risk recipients, such as those rou-
tinely receiving transfusions, though success varies according to 
specific needs of ethnic groups transfused outside their native 
region, where erythrocyte Ag group distribution differs from 
their own. Further, if inflammation fuels alloimmunization, 
some genetic control of responders vs. non-responders – or more 
TABLe 2 | Platelet granule main contents.
α granules δ granules T granules Lysosomes
Adhesion molecules
αIIbβ3, αVβ3, CD9, fibronectin, GPIbα, multimerin, osteonectin, 
PECAM, P-selectin, vitronectin, vWF
Cytokines/chemokines
β-thromboglobulin, CCL4, CCL17, ENA-78, Gro-α, IL-1, IL-7, IL-8, 
MCP-1, MCP-3, MIP-1α, NAP-2, PF4, RANTES, sCD40L, SDF-1
Angiogenesis/growth factors
ADAM10, ADAMTS13, angiostatin, angiopoietin-1, BDNF, bFGF,  
BMP-2, BMP-4, BMP-6, CTAP-III, CTGF, EGF, endostatin, HGF, 
HGR, IGF-1, kininogen, MMP-1, MMP-2, MMP-9, PDGF, TGF-β, 
thrombospondin, TIMP-1, TIMP-4, VEGF
Coagulation factors
α2-antiplasmin, α2-antitrypsin, α2-macroglobulin, antithrombin,  
factor V–VIII–XI–XIII, fibrinogen, PAI-1, plasmin, plasminogen, 
protease nexin-2, protein S, prothrombin, TFPI
Immune mediators
β1H globulin, C1 inhibitor, complement factors, factor D, IgA, IgG, IgM, 
platelet factor H, thymosin-β4
Others
Albumine, PDCI
Nucleotides
ADP, ATP
Cations
Calcium, magnesium
Bioactive amines
Serotonin, histamine
GTP-ases
rab27a, rab27b
Membrane proteins
αIIbβ3, CD63, GPIb,  
LAMP-1, LAMP-2, P-selectin
Others
Polyphosphate, pyrophosphate
PDI
TLR-9
VAMP-8
Acid proteases
Acid phosphatase, arylsulphatase
Carboxypeptidase A–B, cathepsin 
D–E, collagenase, elastase, proline 
carboxypeptidase
Acid hydrolases
α-arabinofuranosidase, 
α-fucosidase, β-fucosidase, 
α-galactosidase, β-galactosidase, 
β-glucoronidase, α-mannosidase, 
α-glucosidase, β-glucosidase, 
β-N-acetyl-hexosaminidase
Membrane proteins
CD63, LAMP-1, LAMP-2
ADP, adenosine diphosphate; ATP, adenosine triphosphate; BDNF, brain-derived neurotrophic factor; bFGF, basic fibroblast growth factor; BMP, bone morphogenetic protein; 
C, complement; CTAP-III, connective tissue-activating peptide III; CTGF, connective tissue growth factor; EGF, epidermal growth factor; HGF, hepatocyte growth factor; HGR, 
histidine-rich glycoprotein; Ig, immunoglobulin; IGF, insulin-like growth factor; IL, interleukin; LAMP, lysosomal-associated membrane protein; MCP, monocyte chemotactic protein; 
MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; NAP, neutrophil-activating protein; PAI, plasminogen activator inhibitor; PDCI, platelet-derived collagenase 
inhibitor; PDGF, platelet-derived growth factor; PDI, protein disulfide isomerase; PECAM, platelet endothelial cell adhesion molecule; PF, platelet factor; RANTES, regulated on 
activation normal T cell expressed and secreted; SDF, stromal cell-derived factor; TFPI, tissue factor pathway inhibitor; TGF, transforming growth factor; TIMP, tissue inhibitor of 
metalloproteinases; TLR, toll-like receptor; VEGF, vascular endothelial growth factor; VAMP, vesicle-associated membrane protein; vWF, von Willebrand factor.
FiGURe 1 | The figure cartoons the platelet’ main granules and their secretory content. Most products that can be released by platelets are listed in 
complementary Table 2.
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precisely, good vs. bad HLA presenters – seems to prevail: this 
has been observed for certain blood group Ags and is very likely 
true for all others (77, 104). The situation is more complex than 
for platelets because the triggers of inflammation are less clearly 
identified. The age of blood is a likely but unproven factor, and 
the effects of storage lesions and erythrocyte Ag alloimmuniza-
tion (105). Various teams have provided indirect evidence after 
examining whether RBC collection can stress RBCs and subse-
quently stress endothelial cells exposed to such RBCs (at least 
in ex vivo/in  vitro models) (106, 107). Here again, until more 
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direct evidence becomes available, one may heed protocols that 
minimize stress to donors’ RBCs and subsequently to recipients’ 
vascular endothelium. Accordingly, some authors recommend 
not overexposing cellular blood components to radiation unless 
absolutely required as this may increase storage lesions (54, 108, 
109). Closer examination is needed to determine the extent 
to which irradiation of BCs favors alloimmunization. Similar 
caution has been suggested for pathogen inactivation/reduction 
technologies, but there are conflicting claims in favor of reduc-
tion or alloimmunization based on impairment of indirect Ag 
presentation (84). This too calls for further investigation.
CONCLUSiON
Transfusion is an old therapy, though it is not obsolete. In fact, it 
is quite modern if seen as cell therapy or biotherapy (110). It is 
very commonly used and is nowadays associated with few noso-
comial AEs. Moreover, not all AEs are truly nosocomial as some 
are in fact linked to characteristics of recipients that can neither 
be dampened nor counteracted by matching blood components. 
When transfusion is associated with AEs, most can be related to 
an inflammatory state, which is either obvious (allergy, FNHTR, 
hypotension) or ascribed to such a state by current knowledge 
(alloimmunization). Indeed, transfusion-transmitted infection 
has become a rarity, and novel means are regularly applied to 
further minimize their occurrence. Means of decreasing the 
occurrence of transfusion-associated inflammation have received 
less attention and care, though they should be our new focus, to 
help patients, secure resources, and limit indirect costs. Platelet 
pathophysiology owes a lot to transfusion medicine: many of the 
major discoveries in this field were made by researchers who, 
questioning the role of PC transfusion in AEs (and occasionally 
SAEs), attempted to solve questions about platelet activation and 
secretion. This review has not considered the other side of the 
coin with respect to platelets and their role in the inflammation 
process. Namely, in addition to being the source of many pro-
inflammatory BRMs, platelets also produce healing factors (the 
terminus of physiological inflammation) that may also be used as 
therapeutic tools (111).
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TABLe 3 | examples of preventable and not yet preventable causes of inflammation in transfusion medicine.
Parameters that can be addressed Parameters that cannot yet be addressed
Donor-related 
parameters
 – So-called irregular antibodies to red blood cells or HLA
 – Autoantibodies
 – Potentially: allergens and IgE antibodies to allergens
 – Infectious pathogens and infectious pathogen-derived material (toxins, 
residues, superantigens)
 – …
Genetic parameters predisposing to inflammation
Processed 
component- 
related  
parameters
 – Typically: leukocytes
 – Microvesicles/microparticles
 – All types of storage lesions
 – Age of blooda
 – …
Recipient-related 
parameters
 – Certain therapies (drugs)  – Genetic parameters that predispose to inflammation
 – Clinical state (causal disease or treatment being the cause of 
the transfusion need)
 – Most therapies, otherwise needed
 – Preexisting alloimmune Abs, autoimmune Abs
 – …
Standard of 
operation 
parameters (SOP)
 – Main blood group matching
 – Blood component freshnessa
 – Fine-tuned blood group matching
aAge of blood appears to fall into either category as it affects the release of biological response modifiers (storage lesions) and likely sustains TRIM, and it affects the release of, e.g., 
oxygen (SOP) and the recirculation or cells (and propensity to apoptosis or to be prone to phagocytosis).
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